Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 28

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 28
---
 and development activities and operations generally, the growth of our business and, if any of our product candidates receive
marketing approval, commercialization activities. We also expect to continue to incur expenses as a result of operating as a public company,
including expenses related to compliance with the rules and regulations of the SEC, additional director and officer insurance expenses,
investor relations activities, and other administrative and professional services.

Other
Income, Net

Other
income, net includes interest earned on deposits and investments and other items of income and gain and loss that are incidental to the
core operations of the Company.

Results
of Operations

Three
months ended September 30, 2025 compared to three months ended September 30, 2024

The
following tables set forth our results of operations for the three months ended September 30, 2025 and 2024 and the relative dollar change
between the two periods.

    Three months ended  

    September
    30,  
    Change 

    2025  
    2024  
    ($)  
    % 
  
    Operating expenses: 

    Research and development 
    $1,517,723  
    $1,466,037  
    $51,686  
     3.5%
  
    General and administrative 
     1,130,764  
     1,676,020  
     (545,256) 
     (32.5)%

    Total operating expenses 
     2,648,487  
     3,142,057  
     (493,570) 
     (15.7)%

    Loss from operations 
     (2,648,487) 
     (3,142,057) 
     493,570  
     (15.7)%

    Other income, net 
     39,088  
     73,021  
     (33,933) 
     (46.5)%
  
    Change in fair value of
    convertible promissory notes 
     (365,718) 
     -  
     (365,718) 
     100%

    Net loss 
    $(2,975,117) 
    $(3,069,036) 
    $93,919 
     3.1%
  
    Net loss attributable
    to common stockholders per share, basic and diluted